by Clinical Neuropsychologist | Wednesday, August 14, 2024 | Dementia
Abstract INTRODUCTION Brain glucose hypometabolism, indexed by the fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) imaging, is a metabolic signature of Alzheimer’s disease (AD). However, the underlying biological pathways involved in these...
by Clinical Neuropsychologist | Wednesday, August 14, 2024 | Dementia
Abstract INTRODUCTION The incidence of Alzheimer’s disease (AD) and obesity rise concomitantly. This study examined whether factors affecting metabolism, race/ethnicity, and sex are associated with AD development. METHODS The analyses included patients ≥ 65...
by Clinical Neuropsychologist | Wednesday, August 14, 2024 | Dementia
Abstract INTRODUCTION Well-chosen biomarkers have the potential to increase the efficiency of clinical trials and drug discovery and should show good precision as well as clinical validity. METHODS We suggest measures that operationalize these criteria and describe a...
by Clinical Neuropsychologist | Tuesday, August 13, 2024 | Dementia
Abstract BACKGROUND Education influences brain health and dementia. However, its impact across regions, specifically Latin America (LA) and the United States (US), is unknown. METHODS A total of 1412 participants comprising controls, patients with Alzheimer’s...
by Clinical Neuropsychologist | Tuesday, August 13, 2024 | Dementia
Abstract INTRODUCTION In this study, we investigated biomarkers in a midlife, racially diverse, at-risk cohort to facilitate early identification and intervention. We examined neuroimaging measures, including resting state functional magnetic resonance imaging (fMRI),...